Advanced AI technologies are starting to play a bigger role in TAVR care, helping cardiologists plan ahead, make critical decisions and predict potential complications. Looking to the future, though, it is clear this is just the beginning. 

For years, imaging experts have predicted that CCTA may become the primary imaging modality for coronary artery disease and eliminate the need for invasive diagnostic catheterizations. That prediction is now coming true.

The new deep learning algorithm is capable of detecting signs of coronary microvascular dysfunction in seconds.

The ACC and AHA both issued new statements on noninvasive CCTA offerings that use advanced AI to evaluate patients with suspected CAD. These technologies have gained significant momentum in recent years, and experts agree that they represent a game-changing advancement in the world of cardiovascular imaging.

San Diego-based Vektor Medical first secured FDA clearance for the AI-powered technology back in 2021. This updated announcement covers the latest version, which includes atrial flutter mapping and several other new features.

The new software, announced at RSNA 2025 in Chicago, was built to evaluate CCTA images for signs of coronary artery disease and improve cath lab efficiency. 

According to Heartflow, its AI offering saves health systems nearly $1,400 per patient thanks to reductions in unnecessary cardiovascular testing.

Researchers put an advanced AI model to the test, using it to evaluate the ECG results of more than 1,000 patients. It performed quite well.